

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

Nome	Giampiero Girolomoni
Qualifica	Professore Ordinario e Direttore Sezione Dermatologia e Venereologia, Dipartimento di Medicina, Scuola di Medicina e Chirurgia, Università di Verona; Direttore della U.O.C. Dermatologia dell'Azienda Ospedaliera Universitaria Integrata di Verona Docente Dermatologia e Venereologia presso il Centro Interdipartimentale di Scienze Mediche – CISMED, Università di Trento
Telefono ufficio e E-mail	045/8122547; giampiero.girolomoni@univr.it

**TITOLI DI STUDIO E
PROFESSIONALI –
ESPERIENZE LAVORATIVE**

Titoli di studio	1976 Diploma di maturità classica – Liceo Mamiani, Pesaro 1983 Laurea in Medicina e Chirurgia – Università di Modena Iscritto Ordine dei Medici PU1622
Altri titoli di studio	1986 Specialista in Dermatologia e Venereologia– Università di Modena
Esperienze professionali (incarichi ricoperti)	1988–1990 Immunodermatology Fellow, Visiting Instructor, Dipart. di Dermatologia, University of Texas Southwestern Medical School, Dallas, TX, USA 1990–1994 Assistente Medico, Clinica Dermatologica, Università di Modena 1994–2004 Direttore Laboratorio di Ricerca di Immunologia; Primario Seconda Divisione di Dermatologia, Direttore Dipartimento di Dermatologia Clinica, Istituto Dermopatico dell'Immacolata, Roma 2005–2018 Direttore scuola di specializzazione in Dermatologia e Venereologia, Università di Verona
Capacità linguistiche	Ottima conoscenza scritta e parlata della lingua inglese
Premi e Onorificenze	1990 Outstanding Research Award: The Upjohn Company and the Department of Dermatology, UTSMD, Dallas, TX 1993 Scientific award: 2 nd Tricontinental Meeting JSID/SID/ESDR. Kyoto 2015 Pro-meritis Award: 2015 European Dermatology Forum, Bern 2016 Ehrenmitglied, Deutsche Dermatologische Gesellschaft 2017 Commendatore, Ordine al Merito della Repubblica Italiana, Presidenza del Consiglio dei Ministri 2017 Scientific Achievement Award, European Academy of Dermatology and Venereology, Geneva 2018 Marchigiano dell'Anno 2017. Centro Studi Marche “Giuseppe Giunchi” – Senato della Repubblica 2018 Membro corrispondente Società Svizzera di Dermatologia e Venereologia 2019 Presidente emerito Società Italiana di Dermatologia (Sidemast) 2020 Certificate of appreciation International League of Dermatological Societies 2023 Cenacolo della Cultura e delle Scienze. Premio “Milano Cultura 2023”
Attività Scientifiche	Fisiopatologia delle reazioni immunitarie cellulo-mediate della cute, immunofarmacologia ed epidemiologia delle malattie infiammatorie croniche della cute. Dermatologia clinica: malattie cutanee nell'immunodepresso, reazioni cutanee da farmaci, manifestazioni cutanee delle malattie interne, complicanze

	cardio-metaboliche delle malattie infiammatorie croniche. Esperienze acquisite nel settore scientifico oggetto di sperimentazione secondo le norme di Buona Pratica Clinica (GCP), maturate nell'ambito di numerosi studi clinici nonché dell'assistenza ai pazienti. Principal investigator in oltre 150 trial clinici internazionali e nazionali. Past president European Dermatology Forum (EDF; 2011–2012) e Società Italiana di Dermatologia (Sidemast; 2014–2016). Editor della sezione Clinical Immunology di Vaccines (Basel). Associate Editor di Frontiers in Medicine (Dermatology). Membro del Comitato editorial di European Journal of Dermatology, the Journal of the German Society of Dermatology, the Journal of Dermatology, European Annals of Allergy and Clinical Immunology. Presidente e/o responsabile scientifico di 178 congressi nazionali o internazionali. Letture a invito 1988–2025:1022.
--	--

Pubblicazioni Scientifiche	Co-autore di 560 articoli originali, 230 reviews, 97 capitoli di libri o monografie, 1175 abstracts per congressi, e co-autore o co-editore di 7 libri. IF medio = 5.18; Citazioni >47000; H-index: 116, i10 H-index: 482 (Scholar). ORCID: 0000-0001-8548-0493; Scopus ID: 7005176426; Publons ID: AAC-3405-2022
-----------------------------------	---

PRINCIPALI PUBBLICAZIONI 2023–2025

1. Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoroso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Girolomoni G, Guarneri C, Loconsole F, Sampogna F, Travaglini M, Malagoli P, Costanzo A. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicenter retrospective study – IL PSO (Italian Landscape Psoriasis). *J Eur Acad Dermatol Venereol* 37:93–103, 2023.
2. Maurelli M, Gisondi P, Girolomoni G. Tailored biological treatment for patients with moderate to severe psoriasis. *Expert Rev Clin Immunol* 19:37–43, 2023.
3. Gisondi P, Maurelli M, Costanzo A, Esposito M, Girolomoni G. The combination of dupilumab with other monoclonal antibodies. *Dermatol Ther (Heidelb)* 13:7–12, 2023.
4. Mattiucci A, Girolomoni G, Cassina M, Zollert, Antoniazzi F, Schena D. Cantú Syndrome: a new case report and evolution of clinical conditions during first two-year follow-up. *Clin Case Rep* 11:e6928, 2023.
5. Maurelli M, Gisondi P, Girolomoni G. Advanced glycosylated end products and psoriasis. *Vaccines (Basel)* 11:617, 2023.
6. Bellinato F, Adami G, Furci A, Cattani G, Schena D, Girolomoni G, Gisondi P. Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab. *JAAD Int* 11:72–77, 2023.
7. Bellinato F, Gisondi P, Marzano AV, Piaserico S, De Simone C, Damiani G, Argenziano G, Venturini M, Dapavo P, Costanzo A, Megna M, Prignano F, Burlando M, Satolli F, Carugno A, Pezzolo E, Romanelli M, Cuccia A, Girolomoni G. Characteristics of patients experiencing a flare of generalized pustular psoriasis: a multicenter observational study. *Vaccines (Basel)* 11:740, 2023.
8. Chiricozzi A, Girolomoni G. Shedding the light on novel pathogenic and therapeutic aspects related to immune-mediated skin diseases. *Vaccines (Basel)* 11:761, 2023.
9. Gisondi P, Geat D, Colato C, Girolomoni G. Recurrent cutaneous eosinophilic vasculitis characterized by annular purpuric lesions: a case report. *SAGE Open Med Case Rep* 11:2050313X231163636, 2023.
10. Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. *J Clin Med* 12:2701, 2023.
11. de Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Thyssen JP, Weidinger S. The treat-to-target project in atopic dermatitis: one year on. *Acta Derm Venereol* 103:adv5382, 2023.
12. Bellinato F, Gisondi P, Fassio A, Girolomoni G. Central pain sensitization in patients with chronic plaque psoriasis or psoriatic arthritis. *Dermatol Ther (Heidelb)* 13:1149–1156, 2023.
13. Maurelli M, Colato C, Gisondi P, Girolomoni G. Eosinophilic annular erythema successfully treated with cyclosporine. *Ital J Dermatol Venerol* 158:158–160, 2023.
14. Maurelli M, Girolomoni G, Gisondi P. Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience. *J Dermatolog Treat* 34:2218504, 2023.
15. Bellinato F, Moar A, Rosina P, Gisondi P, Girolomoni G. Comparative dermoscopy assessment of nevus-associated versus de novo in situ melanoma. *Eur J Dermatol* 33:121–125, 2023.
16. Chiricozzi A, Dal Bello G, Gori N, Di Nardo L, Schena D, Caldarola G, Maurelli M, De Simone C, Girolomoni G, Peris K. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study. *J*

Dermatolog Treat 34:2235041, 2023.

17. Gargiulo L, Ibba L, Malagoli P, Amoroso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Sampogna F, Travaglini M, Costanzo A, Narcisi A. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study – IL PSO group (Italian landscape psoriasis). *Front Med (Lausanne)* 10:1196966, 2023.
18. Zuberbier T, Latiff AA, Agell H, Aggelides X, Alt C, Amagai M, Angileri L, Arruda LK, Augustin M, Balan RG, Bangert C, Bardolet L, Baughman L, Beck L, Bieber T, Berkels R, Bernstein JA, Bertolin Colilla M, Berardi A, Bedbrook A, Bijukchhe A, Bindslev-Jensen C, Borres M, Bousquet J, de Bruin-Weller M, Bruscky D, Buyuktiryaki B, Canonica W, Castro C, Cattaneo A, Catlett G, Chanturidze N, Chong-Neto HJ, Chu CY, Chularojanamontri L, Cork M, Cortez G, Craido R, Curto Barredo L, Custovic A, Dabov F, Darsow U, Emurlai A, De Bruin-Weller M, De Freijo S, De Pablo A, Del Giacco S, Girolomoni G, Deleva Jovanova T, Deleuran M, Diemert S, Douladiris N, Duarte B, Dubakiene R, Dykukha I, Eller E, Engel-Yeger B, Ensina LF, Ferrucci SM, Filho NR, Fisher C, Flohr C, Fomina D, Francuzik W, Galimberti ML, Gattolin G, Giménez-Arnau AM, Godse K, Gotthard Mortz C, Gotua M, Grundhuber MT, Hamza M, Hide M, Hoetzenecker W, Hunzelmann N, Iachetti F, Irvine A, Jack C, Jackson Z, Kamegash A, Kanavarou I, Kaplan D, Katoh N, Kinaciyan T, Kocatürk E, Kornyeveva E, Kulthanan K, Lacour JP, Lapeere H, Lau S, Liska M, Machado Forti Natri M, Makris M, Mansur E, Marsland A, Masuda K, Medina I, Morelo Rocha Felix M, Mosch T, Moschione Castro AP, Nettis E, Nicolas JF, Nikoli A, Nosbaum A, Obando Chancay XD, Odemyr M, Papapostolou N, A S Parisi C, Paudel S, Paul C, Peter J, Pokharell P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid-Grendelmeier P, Serra-Baldrich E, Siemens K, Smith C, Södergren E, Staubach P, Stevanovic K, Strozzi D, Su J, Su-Küçük Ö, Sussman G, Tabilo Bocic T, Tamay Z, Hoon Tan S, Tavecchio S, Teovska Mitrevska N, Thachi D, Toubi E, Traidl-Hoffmann C, Treudler R, Vadasz Z, van Hofman I, Velasco Pastor AM, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Yew Y, Zheng R, Zhao Z, Zwiener R, Worm M. A concept for integrated care pathways for atopic dermatitis – A GA²LEN ADCARE initiative. *Clin Transl Allergy* 2023:e12299.
19. Maurelli M, Gisondi P, Bellinato F, Mantovani A, Targjer G, Girolomoni G. Prevalence of non alcoholic fatty liver disease in adult individuals with moderate-to-severe atopic dermatitis. *J Clin Med* 12:6057, 2023.
20. Bellinato F, Gisondi P, Mioso G, Mason E, Straiotto, D, Piaserico S, Girolomoni G. The transition from mild to moderate-to-severe chronic plaque psoriasis. *J Eur Acad Dermatol Venereol* 37:e1215–e1217, 2023.
21. Chiricozzi A, Ortoncelli M, Schena D, Gori N, Ferrucci SM, Babino G, Napolitano M, Fagnoli MC, Stingeni L, Calzavara-Pinton P, Romanelli M, Balestri R, Pellegrino M, Parodi A, Bertoldi AM, Palazzo G, Antonelli F, Pitino A, Tripepi G, Fabbrocini G, Balato A, Marzano AV, Girolomoni G, Ribero S, Peris K. Long-term effectiveness and safety of upadacitinib in a real-world setting: an interim analysis through 48 weeks of observation. *Am J Clin Dermatol* 24:953–961, 2023.
22. Girolomoni G, Savage L, Gisondi P, Svensson Å, Mahé E, Augustin M, Puig L. Increasing access to effective systemic treatments in patients with moderate-to-severe psoriasis: narrative review. *Dermatol Ther (Heidelb)* 13:2171–2185, 2023.
23. Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Fosse N, Gáspár K, Gerbens L, Gielier U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Rehbindler EM, Ring J, Rossi M, Roxburgh C, Serra-Baldrich E, Simon D, Szalai ZZ, Szepletowski J, Torrelo A, Werfel T, Flohr C. First update of the living european guideline (EuroGuiDerm) on atopic eczema. *J Eur Acad Dermatol Venereol* 37:e1283–e1287, 2023.
24. Chiricozzi A, Balato A, Di Nardo L, Rossi MT, Babino G, Fagnoli MC, Girolomoni G, Patruno C, Bertoldi A, Gambardella G, Esposito M, Antonelli F, Argenziano G, Peris K. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. *J Am Acad Dermatol*, 89:1251–1253, 2023.
25. Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fagnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi M, Franchi M, Ursileo P, Aloisi E. Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis: 42-month results from the SUPREME 2.0 study. *Clin Cosmet Investig Dermatol* 16:3561–3574, 2023.
26. Maurelli M, Chiricozzi A, Peris K, Gisondi P, Girolomoni G. Atopic dermatitis in the elderly population. *Acta Derm Venereol* 103:adv13363, 2023.
27. Chiricozzi A, Ferrucci SM, Di Nardo L, Gori N, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Caldarola G, De Simone C, Ippoliti E, Torres T, Gkalpakiotis S, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Peris K. Current treatment goals are achieved by the majority of patients with dermatitis patients treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study. *Exp Opin Biol Therapy* 23:1307–1315, 2023.
28. Bellinato F, Ioris T, Pascucci E, Viola F, Gisondi P, Girolomoni G. Long-term follow-up of Zoon balanitis: a retrospective cohort study. *Arch Dermatol Res* 316:44, 2024.
29. Pezzolo E, Schena D, Gambardella A, Rossi M, Calzavara Pinton P, Girolomoni G, Naldi L. Survival, efficacy and safety of

- tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. *J Eur Acad Dermatol Venereol* 38:e11–e13, 2024.
30. Gargiulo L, Ibba L, Malagoli P, Amoroso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. A risankizumab super responder profile identified by long-term real-life observation – IL PSO (ITALIAN LANDSCAPE PSORIASIS). *J Eur Acad Dermatol Venereol* 38:e113–e116, 2024.
 31. Gargiulo L, Ibba L, Malagoli P, Amoroso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Effectiveness, tolerability and drug survival of risankizumab in a real-world setting: a 3-year retrospective multicenter study – IL PSO (ITALIAN LANDSCAPE PSORIASIS). *J Clin Med* 13:495, 2024.
 32. Yosipovitch G, Gooderham MJ, Ständer S, Fonacier L, Szepletowski JC, Deleuran M, Girolomoni G, Su J, Bushmakina AG, Cappelleri JC, Feeney C, Chan G, Thorpe A, Valdez H, Biswas P, Rojo R, DiBonaventura M, Myers DE. Interpreting the relationship among itch, sleep, and work productivity in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE MONO-2. *Am J Clin Dermatol* 25:127–138, 2024.
 33. Stingeni L, Chiricozzi A, Calzavara-Pinton P, Napolitano M, Peris K, Schena D, Patruno C, Rossi M, Foti C, Fargnoli MC, Corazza M, Ferrucci SM, Pigatto PD, Romanelli M, Fabbrocini G, Girolomoni G, Passante M, Romita P, Esposito M, Schettini N, Marzano AV, Tonini G, Marietti R, Casciola G, Argenziano G, Hansel K. AtopyReg®, the prospective Italian patient registry for moderate-to-severe atopic dermatitis in adults: baseline demographics, disease characteristics, comorbidities, and treatment history. *Am J Clin Dermatol* 25:149–160, 2024.
 34. Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Costanzo A, Narcisi A. Drug survival of interleukin inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicentre real-world experience on 5932 treatment courses – IL PSO (Italian Landscape Psoriasis). *Front Immunol* 14:1341708, 2024.
 35. Schipani G, Guarneri F, Quaglino P, Fierro MT, Calzavara-Pinton P, Girolomoni G, Alaibac M, Gatti A, Stinco G, Bassoli S, Corazza M, Melandri D, Sirna R, Simonetti S, Stingeni L, Campanati A, Calvieri S, Pagnanelli G, Panasiti V, Scalvenzi M, Schirripa V, Borgia F, Aztori L, Nisticò SP, Patruno C. Head-neck melanoma: clinical, histopathological and prognostic features of an Italian multicentric study. *JEADV Clin Pract* 3:76–85, 2024.
 36. Brigenti N, Gisondi P, Bellinato F, Girolomoni G. Generalised pustular psoriasis successfully treated with spesolimab: a case report. *SAGE Open Med Case Rep* 12:2050313X241235451, 2024.
 37. Mason E, Pascucci E, Schena D, Girolomoni G. Fast and safe clinical response to sonidegib in a 98-year-old woman affected by locally advanced basal cell carcinoma. *Dermatol Online J* 30:11, 20234.
 38. Matucci-Cerinic M, Ciccia F, Foti R, Giunta A, Loconsole F, Prignano F, Scrivo R, Girolomoni G. Adalimumab in the management of psoriasis and psoriatic arthritis: results from a Delphi investigation. *Rheumatol Immunol Res* 5:49–56, 2024.
 39. Bellinato F, Gisondi P, Balato A, Caldarola G, Cammarata E, Campione E, Carugno A, Conti A, Corazza M, Dapavo P, Dattola A, Di Lernia V, Gasperini M, Panduri S, Prignano F, Satolli F, Spisni E, Girolomoni G. Awareness of obesity among patients with psoriasis. *J Eur Acad Dermatol Venereol* 38:e391–e393, 2024.
 40. Bellinato F, Gisondi P, Dattola A, Costanzo A, Valenti M, De Simone C, Marzano AV, Pezzolo E, Nacca M, Pellacani G, Girolomoni G. Spesolimab in patients with flare of generalized pustular psoriasis: a multicenter case-series. *J Eur Acad Dermatol Venereol* 38:e437–e439, 2024.
 41. Avallone G, Mastorino L, Tavoletti G, Macagno N, Barei F, Schena D, Rossi M, Magnaterra E, Antonelli F, Babino G, Viola R, Gargiulo L, Conforti C, Rapparini L, Errichetti E, Patruno C, Pasqualina R, Roccuzzo G, Maronese CA, Girolomoni G, Gola M, Chiricozzi A, Balato A, Ambrogio F, Narcisi A, Zalaudek I, Gurioli C, Napolitano M, Marzano AV, Foti C, Costanzo A, Piraccini BM, Ferrucci SM, Ortoncelli M, Quaglino P, Ribero S. Clinical outcomes and management of JAK inhibitor-associated acne (JAKne) in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: results from a multicenter retrospective study. *J Am Acad Dermatol* 90:1031–1034, 2024.
 42. Argenziano G, Cusano F, Corazza M, Amato S, Amerio P, Naldi L, Patruno C, Pigatto PD, Quaglino P, Gisondi P, Chiricozzi A, Tonon F, Stingeni L, Calzavara-Pinton P, Wollenberg A, Kinberger M, Arents BW, Aszodi N, Avila Valle GL, Barbarot S, Bieber T, Brough HA, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens LA, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szala I, ZZZ Ist, Szepletowski JC, Torrelo A, Werfel T, Flohr C. Italian S3-Guideline on the treatment of Atopic Eczema – Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). *Ital J Dermatol Venerol* 159:223–250, 2024.
 43. Argenziano G, Cusano F, Corazza M, Amato S, Amerio P, Naldi L, Patruno C, Pigatto PD, Quaglino P, Gisondi P, Chiricozzi

- A, Tonon F, Stingeni L, Calzavara-Pinton P, Wollenberg A, Kinberger M, Arents BW, Aszodi N, Avila Valle GL, Barbarot S, Bieber T, Brough HA, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens LA, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szala I ZZ 1st, Szepietowski JC, Torrelo A, Werfel T, Flohr C. Italian S3-Guideline on the treatment of atopic eczema Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA). *Ital J Dermatol Venerol* 159:251–278, 2024.
44. Argenziano G, Cusano F, Corazza M, Amato S, Amerio P, Naldi L, Patruno C, Pigatto PD, Quaglino P, Gisondi P, Chiricozzi A, Tonon F, Stingeni L, Calzavara-Pinton P, Wollenberg A, Kinberger M, Arents BW, Aszodi N, Avila Valle GL, Barbarot S, Bieber T, Brough HA, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens LA, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szala I ZZ 1st, Szepietowski JC, Torrelo A, Werfel T, Flohr C. Italian S3-Guideline on the treatment of atopic eczema – First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA). *Ital J Dermatol Venerol* 159:279–284, 2024.
 45. Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. *Am J Clin Dermatol* 25:527–540, 2024.
 46. Geat D, Gisondi P, Maurelli M, Puig, Paul C, Thaçi D, Iversen L, Bellinato F, Girolomoni G. Price variability of TNF- α inhibitor biosimilars among European countries. *J Eur Acad Dermatol Venereol* 38:e663–e665, 2024.
 47. Favaro R, Facheris P, Formai A, Gargiulo L, Ibba L, Fiorillo G, Latorre RV, Avagliano J, Narcisi A, Girolomoni G, Mercuri SR, Costanzo A. Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients. *J Autoimmun* 147,103244, 2024.
 48. Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoroso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Travaglini M, Costanzo A, Narcisi A. Long-term effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis: A five-year multicentre retrospective study – IL PSO (Italian landscape psoriasis). *Dermatol Ther (Heidelb)* 14:1649–1657, 2024.
 49. Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegadlo-Mylik MA, Pulka G, Dmowska-Steciewicz M, Kłujśzo E, Rekalov D, Rajzer L, Lee J, Lee M, Rho YH. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate to severe plaque psoriasis. *J Am Acad Dermatol* 91:440–447, 2024.
 50. Gargiulo L, Ibba L, Piscazzi F, Amoroso F, Balato A, Barei F, Bertello M, Burrioni AG, Caccavale S, Ferrucci SM, Foti C, Gaiani FM, Girolomoni G, Malagoli P, Marzano AV, Maurelli M, Napolitano M, Nettis E, Ortoncelli M, Patruno C, Pezzolo E, Ribero S, Romita P, Rossi MT, Zaza I, Costanzo A, Narcisi A. Upadacitinib improves subjective symptoms in patients with atopic dermatitis and concomitant allergic rhinitis or allergic asthma: A 16-week multicenter retrospective study. *J Eur Acad Dermatol Venereol* 38:e743–e746, 2024.
 51. Caldarola G, Raimondi G, Samela T, Pinto L, Pampaloni F, Starace MVR, Diluvio L, Dall'Oglio F, Vagnozzi E, de Felici Del Giudice MB, Balestri R, Ambrogio F, Girolomoni G, Riva SF, Moro F, Atzori L, Gallo G, Ribero S, Simonetti O, Barruscotti S, Boccaletti V, Marzano AV, Bianchi L, Micali G, Piraccini BM, Fagnoli MC, Abeni D, Peris K. Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study. *Front Public Health* 12:1415334, 2024.
 52. Bellinato F, Gisondi P, Medori MC, Maltese P, Cristofoli F, Mareso C, Macchia A, Bertelli M, Girolomoni G. Novel loss-of-function variants in filaggrin exon 3 in patients with severe atopic dermatitis. *Arch Dermatol Res* 316:606, 2024.
 53. Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Di Nardo L, Antonelli F, Coscarella G, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Chiricozzi A, Peris K; MEDaCoTRA Study Group. Successful response to tralokinumab in patients unresponsive, intolerant, or with contraindications to dupilumab and JAK inhibitors: a case series. *J Eur Acad Dermatol Venereol* 38:e852–e854, 2024.
 54. Chiricozzi A, Gori N, Ippoliti E, Maurelli M, Antonelli F, Coscarella G, Rizzo E, Di Nardo L, Girolomoni G, Peris K. Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: a real-world, retrospective study. *J Eur Acad Dermatol Venereol* 38:e892–e895, 2024.
 55. Gargiulo L, Ibba L, Alfano A, Malagoli P, Amoroso F, Balato A, Barei F, Burrioni AG, Caccavale S, Calzavara-Pinton P, Esposito M, Fagnoli MC, Ferrucci SM, Foti C, Girolomoni G, Gola M, Guanti MB, Gurioli C, Magliulo M, Maurelli M, Morrone P, Musumeci ML, Napolitano M, Ortoncelli M, Patruno C, Piraccini BM, Pezzolo E, Ribero S, Rossi M, Savoia P, Sciarrone C, Tirone B, Vaccino M, Veronese F, Costanzo A, Narcisi A. Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis). *J Dermatolog Treat* 35:2411855, 2024.
 56. Caushaj R, Bellinato F, Gisondi P, Girolomoni G. Pretibial dystrophic epidermolysis bullosa successfully treated with

upadacitinib: A case report. *Ann Case Rep* 9:101951, 2024.

57. Gargiulo L, Ibba L, Malagoli P, Amoroso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Travaglini M, Costanzo A, Narcisi A. Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis). *J Eur Acad Dermatol Venereol*. 38:e946-e949, 2024.
58. Quaglini P, Argenziano G, Dika E, Starace M, Amabile S, Fava P, Moscarella E, Piraccini BM, Delarue A, Dialla O, Zumaglini F, Girolomoni G. Impact of xerosis in patients with cancer receiving epidermal growth factor receptor or mitogen-activated protein kinase inhibitors: ATIXI, a non-interventional, prospective, pilot study. *Dermatol Pract Concept* 14:e2024259, 2024.
59. Bellinato F, Marocchi M, Pecoraro L, Zaffanello M, Del Giglio M, Girolomoni G, Piacentini G, Rigotti E. Diagnosis and treatment of infantile hemangioma from the primary care paediatricians to the specialist: a narrative review. *Children* 11:1397, 2024.
60. Girolomoni G, Feldman S, Egeberg A, Puig L, Jung J, Jung H, Lee Y. Long-term real-world data of SB5 (Adalimumab Biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). *J Dermatolog Treat* 35:2434091, 2024.
61. Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegadlo-Mylik MA, Pulka G, Dmowska-Stecewicz M, Kłuszo E, Rekalov D, Rajzer L, Lee J, Lee M, Rho Y. Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. *J Dermatolog Treat* 35:2436607, 2024.
62. Bellinato F, Rizzo PC, Antonini P, Gisondi P, Girolomoni G, Colato C. Sézary syndrome with large cell transformation and T-follicular helper phenotype. *JAAD Case Rep* 53:101-104, 2024.
63. Maurelli M, Gisondi P, Girolomoni G. Cost per responder analysis of abrocitinib versus dupilumab in moderate to severe atopic dermatitis. *Ital J Dermatol Venerol* 159:607-611, 2024.
64. Stingeni L, Ferrucci SM, Amerio P, Foti C, Patruno C, Girolomoni G. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. *Exp Opin Biol Ther* 25:15-20, 2025.
65. Brigenti N, Bardelli R, Paolino G, Danese E, Gisondi P, Zerbinati N, Girolomoni G, Carugno A. Midline anterior neck inclusion cyst in a pediatric patient: a case report and literature review with a dermatologic perspective. *Medicina (Kaunas)* 61:64, 2025.
66. Gisondi P, Montalto E, Curic T, Danese E, Bellinato F, Girolomoni G. Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report. *SAGE Open Med Case Rep* 13:2050313X241311374, 2025.
67. Stingeni L, Fargnoli MC, Guarneri F, Balato A, Corazza M, Fortina AB, Calzavara Pinton P, Costanzo A, Ferrucci SM, Naldi L, Pellacani G, Peris K, Prignano F, Girolomoni G. Italian expert opinion on chronic hand eczema: from guidelines to clinical practice. *Dermatol Ther (Heidelb)* 15:75-93, 2025.
68. Napolitano M, Esposito M, Fargnoli MC, Girolomoni G, Romita P, Nicoli E, Matruggio P, Foti C. Infections in patients with atopic dermatitis and the influence of treatment. *Am J Clin Dermatol* 26:183-197, 2025.
69. Ferrucci S, Tavecchio S, Maronese CA, Balato A, Di Brizzi E, Ortoncelli M, Ribero S, Girolomoni G, Maurelli M, Belloni Fortina A, Caroppo F, Naldi L, Pezzolo E, Nettis E, Pugliese F, Stingeni L, Hansel K, Rubegni G, Calabrese L, Russo F, Gola M, Magnaterra E, Rongioletti F, Mercuri SR, Paolino G, Savoia P, Veronese F, Foti C, Ambrogio F, Scalvenzi M, Napolitano M, Patruno C, Dastoli S, Corazza M, Borghi A, Calzavara-Pinton PG, Rossi M, Offidani A, Radi G, Bonzano L, Ferrelli C, Piras V, Satta R, Sucato F, Malagoli P, Gaiani F, Micali G, Musumeci ML, Fargnoli MC, Esposito M, Grieco T, Chello C, Casazza G, Marzano A. Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study on 2576 patients. *Clin Exp Dermatol* 49:1561-1572, 2025.
70. Gisondi P, Bellinato F, Galeone C, Turati F, Idolazzi L, Zabotti A, McGonagle D, Girolomoni G. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. *Ann Rheum Dis* 84:435-441, 2025.
71. Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti MB, Caroppo F, Belloni Fortina A, Patruno C, Campanati A, Bianchelli T, D'Agostino GM, Nettis E, Pugliese F, Di Vico F, Trave I, Cozzani E, Stingeni L, Hansel K, Dall'Olio M, Grigolato L, Coppola R, Panasi V, Maurelli M, Girolomoni G, Ortoncelli M, Ribero S, Marzano AV, Ferrucci SM. Effectiveness of tralokinumab across atopic dermatitis phenotypes. *J Clin Med* 14:2077, 2025.
72. Chiricozzi A, Levi A, Palladino C, Girolomoni G. Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review. *Front Med (Lausanne)* 12:1574697, 2025.
73. Leo F, Ortoncelli M, Cascio Ingurgio R, Galli B, Grigolato L, Paganini C, Maurelli M, Di Brizzi EV, Lauletta G, Barei F, Fiasconaro CA, Casale Alloa M, Guanti MB, Gori N, Chiricozzi A, Napolitano M, Patruno C, Galluzzo M, Rossi M, Balato A, Ferrucci SM, Marzano AV, Pezzolo E, Foti C, Girolomoni G, Gargiulo L, Narcisi A, Quaglini P, Ribero S, Mastorino L. Safety and effectiveness of upadacitinib in patients with moderate-to-severe atopic dermatitis who smoke: a 2-year real-life multicenter study. *Am J Clin Dermatol* 26:425-435, 2025.
74. Piraccini BM, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, Caro G, Rossi A, Pellacani G, Lacarruba F, Micali G, Dall'Oglio F, Vastarella M, Cantelli MT, Patrì A, Nappa P, Diluvio L, Bianchi L, Sechi A, Luigi N, Tassone F, Peris K, Caldarola

- G, Girolomoni G, Marangoni F, Bellinato F, Gisondi P, Scandagli I, Prignano F, Pimpinelli N, Tomasini C, Barruscotti S, Offidani A, Simonetti O, Ambrogio F, Foti C, Boccaletti V, Fraghi A, Marzano AV, Poliaghi G, Sica M, Caprino M, Gallo G, Quaglini P, Balestri R, Ioris T, Caposiena RD, Zalaudek I, Vagnozzi E, Fagnoli MC, Caponio C, Rubegni P, Cinotti E, Trovato E, Romanelli M, Dini V, Manzo Margiotta F, Feliciani C, Del Giudice B, Atzori L, Sanna S, Lembo S, Raimondo A, Magnano M, Starace M. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: a 24-week Italian study. *J Eur Acad Dermatol Venereol* 39:1143–1151, 2025.
75. Gori N, Quaglini P, Chiricozzi A, Marzano AV, Argenziano G, Girolomoni G, Bianchi L, Fagnoli MC, Ortoncelli M, Di Nardo L, Ferrucci SM, Caccavale S, Maurelli M, Galluzzo M, Esposito M, Peris K. Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis. *J Eur Acad Dermatol Venereol* 39:e547–e549, 2025.
 76. Potestio L, Patruno C, Narcisi A, Costanzo A, Ibba L, Gargiulo L, Malagoli P, Ortoncelli M, Ribero S, Mastorino L, Leo F, Ferrucci SM, Angileri L, Barei F, Stingeni L, Hansel K, Sciarrone C, Girolomoni G, Maurelli M, Foti C, Tirone B, Balato A, Esposito M, Paolino G, Mercuri SR, Pezzolo E, Savoia P, Brescia C, Napolitano M. Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study–IL AD (Italian Landscape Atopic Dermatitis). *Arch Dermatol Res* 317:777, 2025.
 77. Savoia P, Gironi LC, Airoidi C, Zottarelli F, Alaibac M, Ardigo M, Argenziano G, Astorino S, Bianchi L, Calzavara-Pinton PG, Congedo M, Fagnoli MC, Foti C, Frascione P, Girolomoni G, Bellinato F, Guarneri F, Lembo S, Longo C, Marzano AV, Micali G, Lacarruba F, Nisticò SP, Offidani A, Peris K, Di Stefani A, Pimpinelli N, Grandi V, Piraccini BM, Quaglini P, Romanelli M, Rongioletti F, Rubegni P, Scalvenzi M, Costa C, Sena P, Stingeni L, Tomasini CF, Zavattaro E. Enhancing skin cancer prevention and awareness in the Italian population: insights from the 'Save your Skin' screening campaign. *Dermatol Pract Concept* 15:5350, 2025.
 78. Cheon JH, Ye BD, Armuzzi A, Reider F, Girolomoni G, Puig L, Jung H, Feldman S. The “totality-of-evidence” and “extrapolation” of SB17, an ustekinumab biosimilar. *Exp Opin Biol Ther* 25:615–632, 2025.
 79. Danese E, Curic T, Bellinato F, Colato C, Gisondi P, Girolomoni G. Upadacitinib in refractory cutaneous pseudolymphoma: A case report. *SAGE Open Med Case Rep* 2025:13:2050313X251350370.
 80. Belli R, Dattolo A, Sampogna F, Gubinelli E, Lulli D, Moretta G, Scala E, Sanna L, Megna M, Cannizzaro MV, Parisi M, Luordi C, Scarponi C, Quaranta M, Lolli MG, Silvestri L, Gisondi P, Girolomoni G, Pallotta S, Albanesi C, Mercurio L, Madonna S. Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients. *Front Immunol* 16:1607312, 2025.
 81. Gisondi P, Bellinato F, Curic T, Girolomoni G. Biosimilars for the treatment of moderate to severe chronic plaque psoriasis. *Psoriasis: targets and therapy* 15:401–410, 2025.
 82. Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti MB, Caroppo F, Belloni Fortina A, Patruno C, Campanati A, Bianchelli T, D'Agostino GM, Nettis E, Pugliese F, Picone V, Trave I, Cozzani E, Stingeni L, Hansel K, Dall'Olio M, Galli B, Coppola R, Panasiti V, Maurelli M, Girolomoni G, Ortoncelli M, Ribero S, Marzano AV, Ferrucci S. Efficacy and drug survival of tralokinumab in severe atopic dermatitis: An 18-month multicenter experience. *Clin Exp Dermatol* 50:1373–1384, 2025.
 83. Valenti M, Ibba L, Di Giulio S, Dapavo P, Malagoli P, Marzano AV, Loconsole F, Burlando M, Balato A, Dini V, Megna M, Girolomoni G, Trovato E, Lasagni C, Travaglini M, Guarneri C, Zerbinati N, Ribero S, Gaiani FM, Carrera CG, Cozzani EC, Di Brizzi EV, Michelucci A, Potestio L, Maurelli M, Dragotto M, Mastorino L, Bongiovanni E, Messina F, Sechi A, Moroni R, Costanzo A, Narcisi A. Guselkumab retention, effectiveness, and safety in psoriasis: a 260-week real-world multicenter retrospective study exploring the role of concomitant PsA-IL PSO (Italian Landscape Psoriasis). *Dermatol Ther (Heidelb)* 15:2423–2437, 2025.
 84. Antonazzo IC, Girolomoni G, Patruno C, Langella R, Ottombrino V, Mantovani LG, Cortesi PA. Budget impact analysis of Lebrikizumab for treating severe atopic dermatitis. *Dermatol Ther (Heidelb)* 15:2521–2536, 2025.
 85. Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Holland S, Mortz CG, Nast A, Nygaard U, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepletowski J, Torrelo A, Werfel T, Werner RN, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: Living update. *J Eur Acad Dermatol Venereol* 39:1537–1566, 2025.
 86. Gargiulo L, Ibba L, Cascio Ingurgio R, Alfano A, Amoroso F, Angileri L, Balato A, Barbagallo T, Bellinato F, Brianti P, Burrioni AG, Campanati A, Caroppo F, Carugno A, Dal Bello G, Tolino E, Ferrucci SM, Foti C, Girolomoni G, Gola M, Guanti MB, Gurioli C, Legori A, Loconsole F, Malagoli P, Manzo Margiotta F, Milanese N, Musumeci ML, Napolitano M, Ortoncelli M, Paolino G, Pella P, Pezzolo E, Prestinari F, Simone Ribero S, Rongioletti F, Rossi M, Satolli F, Savoia P, Sciarrone C, Spigariolo C, Stabile G, Costanzo A, Narcisi A. Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study. *J Eur Acad Dermatol Venereol* 39:e807–e811, 2025.
 87. Bellinato F, Adami G, Reatini MA, Cattani G, Canizzaro MV, Peris K, Gisondi P, Girolomoni G. Impact of particulate matter exposure on risk of melanoma: a multicentre case-control study. *J Eur Acad Dermatol Venereol* 38:000–000, 2025.

88. Trave I, Bellinato F, Salvi I, Priano A, Parodi A, Gisondi P, Girolomoni G, Cozzani E. Risk of relapse upon treatment discontinuation in rosacea: an updated systematic review and network meta-analysis of randomized clinical trials. *J Eur Acad Dermatol Venereol* 38:000–000, 2025.
89. Balato A, Belloni Fortina A, Calzavara Pinton P, Corazza M, Costanzo A, Fargnoli MC, Ferrucci SM, Guarneri F, Naldi L, Pellacani G, Peris K, Prignano F, Stingeni L, Girolomoni G. Italian expert opinion on chronic hand eczema: from guidelines to clinical practice. *Dermatol Ther* 00:000–000, 2025.
90. Zavattaro E, Airoidi C, Veronese F, Cammarata E, Alaibac M, Ardigò M, Argenziano G, Astorino S, Bianchi L, Calzavara-Pinton PG, Congedo M, Fargnoli MC, Foti C, Frascione P, Girolomoni G, Bellinato F, Guarneri F, Lembo S, Longo C, Marzano AV, Micali G, Lacarruba F, Nisticò SP, Offidani A, Peris K, Di Stefani A, Pimpinelli N, Grandi V, Piraccini BM, Quaglino P, Romanelli M, Rongioletti F, Rubegni P, Scalvenzi M, Costa C, Sena P, Stingeni L, Tomasini CF, Savoia P. From North to South: exploring Italian sun-exposure habits through the "Save your Skin" campaign. *Eur J Dermatol* 00:000–000, 2025.
91. Bardelli R, Bellinato F, Carugno A, Zerbinati N, Gisondi P, Girolomoni G. Real-life effectiveness of narrowband UVB phototherapy for pityriasis lichenoides: a retrospective study. *Dermatol Reports* 00:000, 2025.
92. Bellinato F, Adami G, Reatini MA, Cattani G, Pileri A, Piraccini BM, Gisondi P, Girolomoni G. Environmental exposure to PM10 and mycosis fungoides: no evidence of increased risk. *J Invest Dermatol* 000:000–000, 2025.
93. Avallone G, Valtellini L, Tavoletti G, Mastorino L, Maurelli M, Di Brizzi EV, Ippoliti E, Barei F, Termini D, Quaglino P, Ortoncelli M, Girolomoni G, Balato A, Gori N, Peris K, Marzano AV, Ferrucci SM, Ribero S. Effectiveness of tralokinumab for moderate-to-severe atopic dermatitis involving the head-and-neck area: A multicentre retrospective cohort study. *Dermatitis* 00:000–000, 2025.
94. Fargnoli MC, Ferrucci SM, Girolomoni G, Campanati A, Foti C, Patruno P, Calzavara-Pinton P, Chiricozzi A, Wiggins S, De Cupis S, Stingeni L. Clinical perspectives on prurigo nodularis: diagnostic challenges and novel treatment options. *It J Dermatol Venereol* 38:000–000, 2025.
95. Danese E, Curic T, Bellinato F, Colato C, Gisondi P, Girolomoni G. Upadacitinib In refractory cutaneous pseudolymphoma: A case report. *JCMS Case Reports* 00:0000, 2025.
96. Salvagno S, Baravalle S, Colato C, Carletto A, Girolomoni G, Gisondi P. Bywaters lesions: Clinical, Dermoscopic, and Histopathological Insights. *Dermatol Pract Concept* 15:e0000000, 2025.
97. Lauletta G, Potestio L, Patruno C, Ferrucci SM, Angileri L, Barei F, Ortoncelli M, Ribero S, Girolomoni G, Malagoli P, Pezzolo E, Narcisi A, Gargiulo L, Guanti MB, Musumeci ML, Ortega R, Gurioli C, Campanati A, Caroppo F, Legori A, Rossi M, Tolino E, D'Erme AM, Milanese N, Sciarrone C, Gola M, Magnaterra E, Grieco T, Satolli F, Loconsole F, Brianti P, Stingeni L, Hansel K, Bertoldi AM, Napolitano M. Effectiveness and safety of tralokinumab for the elderly with atopic dermatitis in a real-world setting–IL AD. *Dermatitis* 00:000–000, 2025.
98. Barei F, Chiei-Gallo A, Narcisi A, Cascio Ingurgio R, Malagoli P, Girolomoni G, Maurelli M, Pezzolo E, Sciarrone C, Gola M, Magliulo M, Savoia P, Esposto E, Burrioni AG, Amoroso F, Bianchi VG, Mercuri SR, Satolli F, De Felici Del Giudice MB, Pella P, Pinto R, Avallone G, Gurioli C, Piraccini BM, Balato A, Di Brizzi EV, Angiler RG, Manzo Margiotta F, Romanelli M, Rossi M, Guanti MB, Lauretta G, Dastoli S, Patruno C, Napolitano M, Ortoncelli M, Ribero S, Marzano AV, Ferrucci S. Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and previous failures of Th2 biologics: a propensity score-matched study. *Clin Exp Dermatol* 38:000–000, 2025.
99. Maurelli M, Gisondi P, Girolomoni G. Gender perspective in the management of psoriasis. *Ital J Dermatol Venerol* 000:000–000, 2025.
100. Barei F, Macchi S, Calzari P, Ribero S, Ortoncelli M, Foti C, Balato A, Di Brizzi EV, Peris K, Gori N, Gurioli C, Piraccini BM, Trave I, Cozzani E, Pezzolo E, Bonzano L, Errichetti E, Corazza M, Nettis E, Gola M, Milanese N, Feliciani C, De Felici Del Giudice MB, Campanati A, Gioacchini H, Micali G, Musumeci ML, Ortega R, Manzo Margiotta F, Romanelli M, Hansel K, Stingeni L, Patruno C, Esposito M, Fargnoli MC, De Berardinis A, Ferrelli C, Calabrese L, Rubegni P, Grigolato L, Galli B, Rossi M, Maurelli M, Girolomoni G, Lauletta G, Napolitano M, Alfano A, Gargiulo L, Narcisi A, Marzano AV, Ferrucci SM. Clinical course of atopic dermatitis after dupilumab discontinuation: a multicenter real-world study. *Clin Exp Dermatol* 38:000–000, 2025.
101. Avallone G, Bombelli A, Valtellini L, Galli B, Rossi M, Maurelli M, Girolomoni G, Gargiulo L, Narcisi A, Di Vico F, Napolitano M, Lazzeri L, Calabrese L, Caccavale S, Balato A, Barei F, Calzari P, Foti C, Trave I, Rongioletti F, Lenti S, Gurioli C, Nettis E, Caroppo F, Errichetti E, Bonzano L, Gori N, Peris K, Lembo S, Del Regno L, Esposito M, Fargnoli MC, Savoia P, Esposto E, Giuffrida R, Guarneri F, Patruno C, Pezzolo E, Stingeni L, Hansel K, Ortoncelli M, Ribero S, Marzano AV, Ferrucci SM. Therapeutic outcomes across JAK inhibitors in prurigo nodularis. *Clin Exp Dermatol* 38:000–000, 2025.
102. Girolomoni G, Gisondi P, Maurelli M. The girl with a pearl earring: a dermatological puzzle. *J Eur Acad Dermatol Venereol* 38:000–000, 2025.
103. Barei F, Calzari P, Macchi S, Ribero S, Ortoncelli M, Foti C, Balato A, Di Brizzi EV, Peris K, Gori N, Gurioli C, Piraccini BM, Pezzolo E, Bonzano L, Errichetti E, Schettini N, Nettis E, Gola M, Milanese N, Feliciani C, De Felici Del Giudice MB, Caroppo F, Belloni Fortina A, Campanati A, Gioacchini H, Manzo Margiotta F, Romanelli M, Hansel K, Stingeni L, Calabrese L, Rubegni P, Lazzeri L, Grigolato L, Galli B, Rossi M, Maurelli M, Girolomoni G, Coronella L, Patruno C, Napolitano M, Alfano

A, Gargiulo L, Narcisi A, Marzano AV, Ferrucci SM. Optimizing dupilumab dosing in atopic dermatitis: real-world evidence. *Dermatitis* 00:000–000, 2025.

104. Gisondi P, Galeone C, Pedone MP, Restelli U, Silvola S, Girolomoni G. Impatto economico-organizzativo della gestione con dupilumab dei soggetti affetti da dermatite atopica grave in Italia. *Clinicoeconomics* 00:000–000, 2025.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del regolamento (UE) 2016/679 (GDPR). Si attesta inoltre la consapevolezza del rispetto alla responsabilità connesse a dichiarazioni mendaci (PDPR 445/2000 art 76).

Verona, 27.08.2025

Prof. Giampiero Girolomoni